Tianjin Development Holdings (HK:0882) has released an update.
Tianjin Development Holdings’ subsidiary, Lisheng Pharmaceutical, has announced plans for a significant share repurchase program and a share award scheme. The repurchase program aims to buy back shares worth between RMB76.5 million and RMB153 million, while the award scheme will distribute restricted shares to key management. These moves are part of strategic maneuvers in the market and are subject to shareholder approval.
For further insights into HK:0882 stock, check out TipRanks’ Stock Analysis page.